NVE Corp (NVEC) Q3 2026 earnings review
Growth Returns, But The Margin Profile Has Changed
NVE Corporation snapped its year-long streak of revenue declines with a 23% YoY surge to $6.22 million. While the headline number is impressive, it benefits from a weak comparison against the 'inventory glut' bottom of FY25. The recovery is real, but it comes at a cost: Gross Margins have compressed significantly (78.6% vs 84.2% a year ago). Despite the margin pressure, strict cost discipline in R&D and SG&A allowed Net Income to rise 11% to $3.38 million. The company is back to growth mode, but investors must accept a 'new normal' in profitability metrics.
🐂 Bull Case
Revenue growth has decisively reversed from -25% a year ago to +23% today. Product sales (+16%) and a massive spike in Contract R&D (+335%) confirm that demand across both segments has stabilized.
Despite rising sales, Total Expenses fell 12% YoY ($1.14M vs $1.30M). Management successfully leveraged SG&A and R&D cuts to drive a 26% increase in Operating Income.
🐻 Bear Case
Gross margin collapsed by 560 basis points YoY (78.6% vs 84.2%). This appears to be a structural shift or mix issue, as margins have remained in the high-70s for two consecutive quarters, well below historical highs.
The effective tax rate jumped to 19.5% from 14.6% a year ago. This tax drag suppressed Net Income growth (11%) well below Revenue growth (23%).
⚖️ Verdict: 🟢
Bullish. The return to double-digit revenue growth and the ability to control OpEx outweigh the margin compression. The business has successfully navigated the cyclical trough.
Key Themes
Product Sales Recovery
Accelerating. Product sales, the company's core engine, grew 16% YoY to $5.78 million. This marks a sharp turnaround from the -22% contraction seen in the year-ago quarter, signaling that the industry-wide inventory destocking phase that plagued FY25 is effectively over.
Gross Margin Compression
Stabilizing (at lower levels). Gross margin came in at 78.6%, down significantly from 84.2% in 25Q3. While this is flat sequentially (26Q2 was 78.3%), it confirms that the 'high-80s' margin profile has degraded. This likely reflects a mix shift toward lower-margin distributor sales or new product ramp-up costs.
Contract R&D Surge
Accelerating. Contract R&D revenue exploded 335% YoY to $446k. While this is small in absolute dollars compared to product sales, it suggests new government or defense-related development contracts are active, which often lead to future product sales.
Fortress Balance Sheet
Stable. The company holds an immense stockpile of cash and marketable securities totaling ~$44 million (Cash $3.4M + Short-term Sec $17.1M + Long-term Sec $23.4M). With zero debt and quarterly liabilities under $1M, the company effectively operates as a high-yield savings account attached to a semiconductor business.
Expense Discipline
Improving. Total Operating Expenses decreased 12% YoY. Notably, R&D expenses dropped 9% ($795k vs $870k) and SG&A dropped 19% ($352k vs $435k). This creates positive operating leverage: Revenue went up 23%, but the cost to run the business went down.
Other KPIs
Rebounding. Operating margin expanded from 58.5% in 25Q3 to 60.1% in 26Q3. The drop in Gross Margin was fully offset by the reduction in Operating Expenses.
Accelerating. EPS grew 11% YoY from $0.63. While solid, it trails the 26% growth in Operating Income due to a higher tax provision ($821k vs $521k) and slightly lower interest income.
Stable. Despite a massive cash pile, interest income was slightly down (-2.5% YoY). This significant non-operating income stream contributes ~11% of Pretax Income.
Guidance
NVE Corporation did not provide specific numeric guidance for 26Q4 or the full fiscal year. The press release relies on standard boilerplate regarding 'future plans' and risks. Note: The company historically does not provide quantitative guidance.
Key Questions
Gross Margin Structural Shift
Gross margins have settled in the high-70s for two consecutive quarters, down from historical mid-80s. Is this 78% range the new normal due to product mix (distributor vs direct), or are there temporary production inefficiencies weighing on profitability?
R&D Revenue Sustainability
Contract R&D revenue tripled this quarter to $446k. Is this driven by a specific new defense contract, and should we model this higher level of contract activity persisting into FY27?
Capital Allocation Strategy
With nearly $44 million in liquid assets and no debt, the cash balance continues to grow. Beyond the dividend, are there plans for more aggressive buybacks or capital investment, especially given the stock's reaction to the recovery?
Expense Reduction Sustainability
Both R&D and SG&A expenses declined significantly year-over-year despite the revenue growth. Are these sustainable structural savings, or was there a timing shift in project spend that will return in Q4?